---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-015247"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:16:19.029975+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology AACR data: onvansertib shows 73% ORR in bev-naive RAS-mutated mCRC vs 19% in bev-exposed

## Summary
- Bev-naive patients in Phase 1b/2 trial had ORR of 73% vs 19% for bev-exposed; odds ratio 13.64 (p<0.001) and PFS HR 0.21 (p=0.003).
- Onvansertib inhibits hypoxia pathway via HIF1α regulation, reducing tumor vascularization; combo with bevacizumab enhances reduction.
- In RAS WT mCRC PDX models, onvansertib as monotherapy induced stasis/regression in 70% (14/20) of models; combo with cetuximab in 90% (18/20).
- In SCLC cisplatin-resistant PDX models, onvansertib + paclitaxel led to tumor regression lasting 2 months post-treatment.
- CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC to randomize 90 patients to onvansertib 20mg or 30mg plus SoC vs SoC alone.

## SEC filing metadata
- accession: 0001628280-24-015247
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/0001628280-24-015247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024015247/crdf-20240408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-015247
- JSON: https://secwatch.observer/filing/0001628280-24-015247.json
- Plain text: https://secwatch.observer/filing/0001628280-24-015247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.